|Bid||9.95 x 800|
|Ask||9.99 x 3000|
|Day's range||9.94 - 9.99|
|52-week range||1.99 - 58.00|
|Beta (5Y monthly)||2.09|
|PE ratio (TTM)||N/A|
|Earnings date||02 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||125.00|
BOCA RATON, Fla., May 31, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies.
BOCA RATON, Fla., May 20, 2022--TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced the FDA’s approval of a supplemental New Drug Application (sNDA) for ANNOVERA. The sNDA included minor revisions to ANNOVERA’s in vitro release testing specification that allowed for normal manufacturing variability.
Thank you for joining us for TherapeuticsMD's first quarter 2020 financial results conference call. Good afternoon, everyone, and thank you for joining today to discuss our first quarter financial results and business update. This afternoon, TherapeuticsMD issued a press release announcing its first quarter 2022 financial results.